Sativex has been developed by the UK-based GW Pharmaceuticals and is marketed in Europe (except the UK) by Almirall.
The Phase III studies demonstrated the long term efficacy of Sativex (2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol per puff) in patients with moderate to severe spasticity due to multiple sclerosis.
Almirall Chief Scientific Officer Bertil Lindmark said the positive results provide an opportunity to help patients with MS spasticity.